Private Equity Healthcare Rollups: A Buyer Diligence Guide Before You Sign

Five public enforcement and oversight matters show what happens when the rollup thesis outpaces the legal and operational facts. Here is how to test the facts before the wire.

By Noah Green CPA CFE

This article is for general diligence education. It is not legal advice, investment advice, tax advice, or a conclusion about any specific transaction. Enforcement posture changes quickly. Verify the current case posture, consent orders, bankruptcy docket, and regulator materials before relying on any example cited here.

The Short Version

Private equity healthcare diligence has to test more than revenue, add-backs, and physician headcount. Public enforcement and oversight materials around USAP, Aspen Dental, Patient Care America, Steward, and EmCare show five recurring diligence questions that a buyer must answer before signing:

Is the platform buying clinical market power, not just operational capacity?
Is the management company crossing the line from administrative support into clinical control?
Do referral payments, commissions, or admission incentives create Anti-Kickback Statute or False Claims Act exposure?
Does the capital structure depend on rent, lease, or debt assumptions that can survive only in the upside case?
Is the buyer inheriting billing, coding, corporate-integrity, or bankruptcy risk from conduct that predated the current owner?

Each question maps to a specific public matter. Each matter points to a specific document request. The goal of this guide is to connect the public record to the pre-signing checklist so a buyer or investor can test the thesis before committing capital.

Public Posture

The five matters used in this guide are at different stages of resolution as of June 2, 2026. Getting the posture right matters because overstating a settlement as a conviction, or treating an agreement in principle as a final order, creates factual errors that undermine the diligence analysis.

USAP and Welsh Carson. The FTC filed its complaint against U.S. Anesthesia Partners and Welsh Carson on September 21, 2023, alleging a rollup strategy that consolidated Texas anesthesia practices and raised prices. Welsh Carson was dismissed from the federal district court case on May 13, 2024. The FTC approved a final administrative order with Welsh Carson on May 20, 2025. The FTC announced an agreement in principle with USAP on April 23, 2026, subject to execution and court approval. The specific structural relief in the USAP agreement was not public in the April 2026 release. Welsh Carson settled without an admission of liability. The USAP matter is not a final order as of the posture verification date.

Aspen Dental California. The California Attorney General announced a settlement with Aspen Dental Management on May 7, 2026. The settlement was subject to court approval as of the announcement. The AG alleged Aspen exceeded a business-support role, interfered with ownership and management of dentistry, used clinician sales incentives, and ran misleading advertising. The announced terms include \$2 million in penalties and a \$300,000 restitution fund, along with injunctive relief. Because the settlement remained subject to court approval, the final terms may differ from the announcement.

Patient Care America and Riordan, Lewis and Haden. DOJ announced a settlement on September 18, 2019. The settlement resolved allegations that a PE-backed compounding pharmacy and its private equity sponsor participated in a kickback scheme involving TRICARE prescriptions. The matter resolved by settlement, not a liability finding. Total announced settlement amount was \$21.36 million across the pharmacy, executives, and the PE firm.

Steward Health Care and Cerberus. Cerberus acquired Caritas assets in 2010. Massachusetts AG monitoring concluded in 2015. Steward filed Chapter 11 on May 6, 2024. Public materials from the Senator Markey report, Massachusetts AG monitoring releases, and bankruptcy filings focus on financial stress, lease obligations, hospital closures, and oversight gaps. No enforcement redress against Cerberus has been identified in the public sources reviewed for this article. Steward is used here as a public oversight and bankruptcy cautionary case, not as a proven enforcement finding against Cerberus.

EmCare and Envision. DOJ announced the EmCare settlement on December 19, 2017. KKR completed its Envision acquisition in 2018. The HHS-OIG corporate integrity agreement page for Envision Healthcare reflects the CIA obligation. Envision filed Chapter 11 in 2023. The 2017 DOJ settlement is useful as a physician-staffing billing-risk example, but publication should not imply KKR caused the pre-acquisition EmCare conduct.

Mechanism or Diligence Problem

Healthcare rollups fail in five distinct ways. Understanding the mechanism is more useful than memorizing the settlement amounts, because the mechanism tells you which documents to request and which numbers to reconcile.

Mechanism 1: Antitrust Concentration Through Serial Acquisitions

The USAP matter is the clearest public example of the antitrust rollup mechanism. The FTC alleged that Welsh Carson and USAP used a strategy of serial acquisitions, price-setting arrangements, and market-allocation agreements to create a dominant anesthesia provider in Texas and raise prices paid by commercial payers and, ultimately, patients.

The mechanism is not complicated. A platform acquires enough providers in a specialty or geography that it controls the supply of that service to hospitals and payers. Once it controls supply, it can negotiate rates that a smaller or independent provider could not achieve. The FTC’s theory is that this process, when it involves agreements among competitors or deliberate market-allocation, violates the antitrust laws regardless of whether each individual acquisition was small enough to avoid pre-merger notification.

The diligence implication is that a buyer cannot evaluate a provider rollup only by looking at the most recent acquisition. The buyer needs to understand the cumulative market position, the history of rate negotiations, and whether any board materials, side letters, or affiliation agreements reflect a deliberate strategy to control pricing or exclude competitors.

Mechanism 2: Corporate Practice Boundary Violations in DSO and MSO Structures

The Aspen Dental California matter illustrates the corporate-practice mechanism. Most states restrict the corporate practice of medicine or dentistry, meaning a non-professional entity cannot own or control a clinical practice. DSOs and MSOs are structured to provide management, staffing, advertising, equipment, and administrative support while leaving clinical ownership and decision-making with licensed professionals.

The California AG alleged that Aspen Dental Management exceeded that support role. The specific allegations in the May 7, 2026 announcement included interference with ownership and management of dentistry, use of clinician sales incentives that the state viewed as compromising clinical judgment, and misleading advertising about pricing, insurance acceptance, and services.

The diligence implication is that the management services agreement is not just a contract to review for economics. It is the document that defines whether the DSO or MSO is operating within the legal boundary. A buyer needs to read the MSA against the applicable state corporate-practice rules, trace who actually controls clinical decisions in practice, and test whether the compensation structure creates pressure on clinicians to generate revenue rather than exercise independent judgment.

Mechanism 3: Kickback and False Claims Act Exposure Through Referral Economics

The Patient Care America matter illustrates the referral-economics mechanism. DOJ alleged that the PE-backed compounding pharmacy paid commissions to marketers who generated prescriptions for expensive compounded creams and vitamins for TRICARE beneficiaries regardless of medical necessity. DOJ further alleged that the private equity firm managed the portfolio company and funded the commission payments.

The mechanism is that a platform’s revenue growth depends on referral payments that violate the Anti-Kickback Statute, and the resulting claims to federal healthcare programs are false claims under the FCA. The PE firm’s involvement in approving or funding the payments is what created the alleged sponsor-level exposure.

The diligence implication is that a buyer needs to trace the full referral chain, not just the top-line revenue. Marketing contracts, commission schedules, lead-generation agreements, and patient-broker arrangements all need to be reviewed against AKS safe harbors. Board minutes and investor approvals that touch referral-payment decisions are material documents, not just background materials.

Mechanism 4: Capital Structure Failure Under Downside Reimbursement

Steward is the clearest public example of the capital-structure mechanism. The public materials show a hospital system that expanded through acquisition, monetized real estate through sale-leaseback transactions, and ultimately filed Chapter 11 in 2024. The Massachusetts AG monitoring materials and the Senator Markey report document the oversight gaps and financial stress that preceded the bankruptcy.

The mechanism is that a healthcare platform’s capital structure depends on reimbursement levels, census volumes, and lease economics that are sustainable only in the upside case. When reimbursement rates decline, patient volumes fall, or lease obligations become unserviceable, the platform cannot generate enough cash to cover its fixed obligations. Hospital closures and service disruptions follow.

The diligence implication is that a buyer needs to model the capital structure under downside cases, not just the base case. Lease burden as a percentage of revenue, capex requirements to maintain licensure and accreditation, minimum service commitments to regulators, and dividend capacity under stress are all diligence questions that belong in the financial model before signing.

Mechanism 5: Successor Liability for Pre-Acquisition Billing and Compliance Conduct

The EmCare and TeamHealth matters illustrate the successor-liability mechanism. The DOJ alleged that EmCare received remuneration from HMA to recommend inpatient admissions when outpatient or observation status should have applied. The settlement was announced in December 2017. KKR’s Envision acquisition closed in 2018. The IPC Healthcare matter, which resolved in a \$60 million settlement announced in February 2017, involved allegations that IPC systematically encouraged upcoding for hospitalist services. Blackstone’s TeamHealth acquisition also closed in 2017.

The mechanism is that a buyer acquires a platform with unresolved billing, coding, or compliance history and inherits the exposure through successor liability, indemnification gaps, or ongoing CIA obligations. The corporate integrity agreement that Envision entered reflects the ongoing compliance burden that a buyer inherits even when the underlying conduct predated the acquisition.

The diligence implication is that a buyer needs to review the full billing and compliance history, not just the period since the current owner acquired the platform. CID history, whistleblower docket checks, prior settlements, CIA obligations, and audit findings are all material to the purchase price and deal structure.

Warning Signs

The following patterns appear across the public matters in this cluster. A buyer who sees more than two of these in a single target should slow down and request additional documentation before proceeding.

Rapid acquisition pace without integration evidence. A platform that has completed ten or more acquisitions in three years but cannot produce integration playbooks, combined billing audits, or consolidated compliance policies is a warning sign. Speed of acquisition is not the same as operational integration.

Rate improvement attributed entirely to scale. When a seller explains contracted-rate increases as the natural result of scale without being able to show the specific payer negotiation history, the buyer should ask for the rate bridge by payer and by acquisition date. If rates increased sharply after specific acquisitions in specific markets, the antitrust question becomes material.

MSA economics that depend on revenue-linked fees. A management services agreement that charges a percentage of revenue, rather than a fixed fee for defined services, creates an economic incentive for the management company to maximize revenue regardless of clinical appropriateness. This structure is a warning sign in any state with corporate-practice restrictions.

Marketing or referral costs that are large relative to clinical costs. A compounding pharmacy, home health agency, or specialty practice that spends more on marketing and referral development than on clinical staff or supplies should prompt a detailed review of the referral economics. Commission payments to non-clinical marketers who generate federally reimbursed claims are a core AKS risk.

Sale-leaseback transactions with related parties. A hospital or clinic system that has sold its real estate to a related party and leases it back at above-market rates is a warning sign for capital-structure stress. The buyer needs to understand whether the lease obligation is serviceable under a downside reimbursement case.

Coding distributions that are outliers relative to specialty benchmarks. A physician-staffing platform whose billing shows a higher percentage of high-complexity codes than specialty benchmarks would predict is a warning sign for upcoding risk. The buyer should request a coding distribution analysis by provider, by facility, and by year before signing.

Corporate integrity agreement obligations that are not disclosed in the data room. A CIA creates ongoing compliance obligations, reporting requirements, and potential exclusion risk. A buyer who discovers a CIA obligation after signing has a structural problem. CIA status should be confirmed through the HHS-OIG CIA database before the LOI is signed.

Diligence Tests Before Signing or Before The Wire

The following tests are organized by the five mechanisms described above. Each test identifies the document to request, the reconciliation to perform, and the red flag that would require further investigation.

Antitrust and Market Power Tests

Document request: All acquisition agreements from the past seven years, including letters of intent, side letters, noncompete agreements, and affiliation agreements with competitors or facilities.

Reconciliation: Build a market-share table by specialty, metro area, and facility. Map the acquisition sequence against contracted-rate changes by payer. If rates increased after specific acquisitions in specific markets, quantify the rate delta and compare it to regional benchmarks.

Red flag: Board materials that describe acquisitions in terms of pricing leverage, market control, or competitor exclusion. Side letters with competitors that allocate markets or set pricing floors. Facility contracts with exclusivity provisions that prevent competing providers from entering.

How to read the source document: In the FTC’s April 23, 2026 release on USAP, the agency described its theory as a rollup strategy that created a dominant provider and raised prices. A buyer reviewing board materials should look for the same language: rollup, consolidation, pricing power, rate lift, market control, and exclusivity. Those words in a board deck are not automatically unlawful, but they are the starting point for an antitrust analysis.

Corporate Practice and MSA Tests

Document request: The management services agreement, all amendments, the dentist or physician ownership agreements, the compensation plan for clinical staff, all advertising materials, and any state regulatory correspondence about the DSO or MSO structure.

Reconciliation: Map the MSA terms against the applicable state corporate-practice statute and any state AG guidance. Identify every decision right that the MSA assigns to the management company rather than the licensed professional. Test whether the compensation plan creates a financial incentive for clinicians to recommend services or products that generate management-company revenue.

Red flag: MSA provisions that give the management company approval rights over clinical hiring, firing, or compensation. Revenue-linked management fees that increase when clinical volume increases. Advertising claims about pricing, insurance acceptance, or service availability that are not substantiated by the actual practice economics.

How to read the source document: The California AG’s May 7, 2026 release on Aspen Dental describes the alleged violations in terms of ownership and management interference, clinician sales incentives, and misleading advertising. A buyer reviewing an MSA should ask whether any provision in the agreement could be characterized in those terms by a state AG applying the same corporate-practice framework.

Referral Economics and AKS Tests

Document request: All marketing contracts, commission agreements, lead-generation agreements, patient-broker agreements, and MSO fee arrangements. Board minutes and investor approvals that reference marketing spend, referral payments, or commission structures. Monthly financials showing referral-payment line items.

Reconciliation: Trace the referral chain from marketing vendor to prescription or referral to claim. Quantify commission payments as a percentage of the revenue generated by the referred claims. Test whether the commission structure fits within an AKS safe harbor.

Red flag: Commission payments to non-clinical marketers that are calculated as a percentage of the value of federally reimbursed claims generated by the referrals. Board minutes that show investor approval of commission structures without legal analysis of AKS compliance. Concentration of revenue in a single federal program, such as TRICARE or Medicare, combined with high marketing costs.

How to read the source document: The DOJ’s Patient Care America settlement release describes the alleged scheme as kickbacks that generated prescriptions regardless of patient need, with the PE firm managing the company and funding the commission payments. A buyer reviewing marketing contracts should ask whether the payment structure could be characterized the same way: payments that generate claims regardless of medical necessity, with investor-level visibility into the payment mechanics.

Capital Structure and Lease Tests

Document request: All lease agreements, sale-leaseback transaction documents, related-party real estate agreements, capex schedules, minimum service commitment agreements with regulators, and financial statements for the past five years including cash flow statements.

Reconciliation: Model lease obligations as a percentage of revenue under base, downside, and stress cases. Identify capex requirements to maintain licensure, accreditation, and minimum service commitments. Test whether the platform can service its lease and debt obligations if reimbursement rates decline by ten percent or census volumes decline by fifteen percent.

Red flag: Lease obligations that exceed fifteen percent of revenue in the base case. Sale-leaseback transactions with related parties at above-market rates. Capex deferrals that have created deferred maintenance obligations. Minimum service commitments to state regulators that cannot be met under the downside case.

How to read the source document: The Massachusetts AG monitoring releases and the Senator Markey report on Steward document the oversight gaps and financial stress that preceded the bankruptcy. A buyer reviewing a hospital or clinic system’s financials should look for the same patterns: rising lease obligations, declining capex, deferred maintenance, and regulatory correspondence about service continuity.

Successor Liability and Compliance History Tests

Document request: All prior DOJ, FTC, HHS-OIG, and state AG correspondence. All prior settlement agreements, CIA obligations, and compliance program documentation. CID history. Whistleblower docket check through PACER. Billing audit history for the past five years.

Reconciliation: Confirm CIA status through the HHS-OIG CIA database before signing. Review the coding distribution by provider, by facility, and by year against specialty benchmarks. Identify any prior settlement that included a corporate integrity obligation and confirm that the obligation has been satisfied or is being monitored.

Red flag: A CIA obligation that is not disclosed in the data room. A coding distribution that shows a higher percentage of high-complexity codes than specialty benchmarks would predict. Prior settlements that included admission-rate or billing-practice restrictions that are still in effect. Whistleblower complaints that have not been resolved.

How to read the source document: The HHS-OIG CIA page for Envision Healthcare reflects the ongoing compliance obligation that followed the EmCare settlement. A buyer reviewing a physician-staffing platform should check the HHS-OIG CIA database directly, not rely on the seller’s representation that no CIA exists. The database is publicly searchable and is the authoritative source.

By the Numbers

Data Point	Public Source Fact	Primary Source	Diligence Meaning
USAP / Welsh Carson antitrust rollup	FTC complaint filed Sept. 21, 2023; Welsh Carson final order May 20, 2025; USAP agreement in principle announced April 23, 2026, subject to execution and court approval	FTC April 23, 2026 release; FTC May 20, 2025 Welsh Carson order	Antitrust rollup risk can survive deal close, restrict future acquisitions, and require structural relief years after the original transactions.
Aspen Dental California DSO settlement	\$2M penalties and \$300K restitution fund announced May 7, 2026, subject to court approval; injunctive relief on ownership control, revenue-linked fees, clinician sales incentives, and advertising	California AG May 7, 2026 release	DSO management fee structures and clinical-control provisions require state-law review before signing. Settlement terms may change pending court approval.
Patient Care America / RLH FCA settlement	\$21.36M total settlement announced Sept. 18, 2019, involving pharmacy, executives, and PE firm; resolved by settlement, not a liability finding	DOJ Sept. 18, 2019 settlement release	Investor-level conduct, including approvals and funding of referral payments, can create FCA and AKS exposure at the sponsor level.
EmCare FCA settlement and Envision CIA	\$29.8M FCA settlement announced Dec. 19, 2017; Envision entered a five-year CIA; Envision filed Chapter 11 in 2023	DOJ Dec. 19, 2017 EmCare release; HHS-OIG Envision CIA page	Billing and referral history from pre-acquisition conduct can become successor diligence. CIA obligations survive ownership changes and must be confirmed through the HHS-OIG database.
TeamHealth / IPC Healthcare FCA settlement	\$60M plus interest settlement announced Feb. 6, 2017, resolving allegations that IPC systematically encouraged upcoding for hospitalist services; Fifth Circuit opinion Aug. 31, 2023 references a \$48M settlement in a separate TeamHealth FCA matter	DOJ Feb. 6, 2017 TeamHealth release; Fifth Circuit opinion Aug. 31, 2023	Coding-distribution outliers in physician-staffing platforms are a pre-acquisition diligence red flag. Prior settlements do not eliminate successor exposure if the underlying billing practices continue.
Steward Health Care bankruptcy	Steward filed Chapter 11 May 6, 2024; Massachusetts AG monitoring concluded in 2015; Senator Markey report documents financial stress and oversight gaps	MA AG monitoring release; Senator Markey report page; MA bankruptcy response release	Sale-leaseback capital structures in hospital systems require downside stress testing. Monitoring agreements and regulatory oversight do not guarantee service continuity or financial stability.
ACFE 2024 occupational fraud baseline	ACFE Report to the Nations 2024 documents median fraud loss, detection methods, and control gaps across industries	ACFE Report to the Nations 2024	Healthcare rollup diligence should include internal control testing, not just financial modeling. Occupational fraud risk increases in high-growth, acquisition-driven platforms where integration controls lag acquisition pace.

Source note: All figures and posture descriptions are drawn from the public primary sources listed in the Primary Sources section. Dollar amounts reflect announced settlement figures, not court-determined liability findings, unless otherwise noted.

Buyer / Investor Takeaway

A buyer or investor entering a healthcare rollup transaction faces a different risk profile than a buyer entering a single-site practice acquisition. The rollup structure concentrates risk in ways that are not visible from the income statement alone.

The antitrust risk is cumulative. Each individual acquisition in a rollup may be small enough to avoid pre-merger notification. The antitrust risk accumulates across the acquisition history. A buyer who acquires a platform with a ten-year acquisition history is acquiring the cumulative market position, not just the most recent deal. The USAP matter shows that the FTC can challenge the rollup strategy as a whole, not just individual transactions.

The corporate-practice risk is jurisdiction-specific. A DSO or MSO structure that is compliant in one state may not be compliant in another. A buyer acquiring a multi-state platform needs a state-by-state corporate-practice analysis, not a single national legal opinion. The Aspen Dental California matter shows that a state AG can challenge a DSO structure even when the platform has operated for years without prior enforcement action.

The FCA and AKS risk travels with the revenue. A platform whose revenue depends on referral payments, commission structures, or admission incentives that do not fit within AKS safe harbors is carrying FCA exposure in its revenue line. A buyer who acquires that revenue without testing the referral economics is acquiring the exposure. The Patient Care America matter shows that the exposure can reach the investor level when the investor manages the platform and funds the payments.

The capital-structure risk is asymmetric. A sale-leaseback transaction that improves short-term returns by monetizing real estate creates a fixed lease obligation that does not decline when reimbursement rates fall. The Steward matter shows that a hospital system can survive years of financial stress before the capital structure fails, and that the failure can be sudden and disruptive to patients, employees, and communities. A buyer needs to test the downside case before signing, not after the platform is in distress.

The successor-liability risk requires a pre-signing public-record sweep. A buyer who discovers a CIA obligation, a prior settlement, or an unresolved whistleblower complaint after signing has a structural problem. The HHS-OIG CIA database, the DOJ settlement archive, the FTC docket, and PACER are all publicly searchable. A pre-signing public-record sweep is not optional diligence. It is the minimum standard for a healthcare acquisition.

Equity rollover participants face the same risks as buyers. A physician-owner who rolls equity into a PE-backed platform is making an investment decision, not just a practice-management decision. The physician needs to understand the platform’s market position, billing practices, referral economics, capital structure, and compliance history before rolling equity. The same diligence framework applies.

SPP Bottom Line

A healthcare rollup buyer should not diligence only the platform’s adjusted EBITDA. Test the legal mechanism that creates the EBITDA. If the growth story depends on market power, clinical-control leakage, referral payments, aggressive billing, or rent structures that fail under a downside case, the buyer needs that answer before signing.

The five public matters in this guide are not a complete inventory of healthcare rollup enforcement. They are five well-documented examples of the five mechanisms that recur most often in the public record. A buyer who understands the mechanism can build the right document request, perform the right reconciliation, and identify the right red flags before committing capital.

SPP’s role is independent buyer-side CPA and CFE diligence: organize the public record, test the economics, identify pre-signing questions, and help the buyer avoid relying on a sales story that the documents do not support. The public record is available to every buyer. The question is whether the buyer reads it before or after the wire.